Journal Article

Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study

De Vita, Ferdinando, Mazza, Elena, Pellino, Antonio, Cascinu, Stefano, Strippoli, Antonia, Lavacchi, Daniele, Antonuzzo, Lorenzo, Spallanzani, Andrea, Di Donato, Samantha, Murgioni, Sabina, Cappetta, Alessandro, Lonardi, Sara, Tirino, Giuseppe, Prisciandaro, Michele, Fornaro, Lorenzo, Vivaldi, Caterina, Pompella, Luca, Catanese, Silvia, Zagonel, Vittorina, Puzzoni, Marco, Aprile, Giuseppe, Nappo, Floriana, Barsotti, Giulia

2023

Overview

Background FLOT regimen is the standard perioperative treatment in Western countries for patients with locally advanced gastric (GC) or gastroesophageal junction cancer (GEJC). High microsatellite instability (MSI-H) and Mismatch Repair deficient (dMMR) demonstrated a favorable prognostic role and a concomitant negative predictive impact on the benefit of perioperative 5-fluorouracil-based doublets; however, its role in pts receiving FLOT chemotherapy is still unclear. Methods This is a retrospective, multicenter observational study of 265 pts with GC/GEJC treated with perioperative FLOT regimen in 11 Italian oncology centers between January 2017 to December 2021 and analyzed for microsatellite status. Results The MSI-H phenotype was found in 27 (10.2%) of 265 analyzed tumors. Compared to microsatellite stable (MSS) and Mismatch Repair proficient (pMMR) cases, MSI-H/dMMR were more frequently female (48.1% vs. 27.3%, p  = 0.0424), elderly pts (age > 70 years, 44.4% vs. 13.4%, p  = 0.0003), Laurens’s intestinal type (62.5% vs. 36.1%, p  = 0.02) and pts with a primary location tumor in the antrum (37 vs. 14.3%, p  = 0.0004). A statistically significant difference in the rate of pathologically negative lymph node emerged (63% vs 30.7%, p  = 0.0018). Compared to the MSS/pMMR tumor population, the MSI-H/dMMR subgroup had a better DFS (median not reached [NR] vs. 19.5 [15.59–23.59] mos, p  = 0.031) and OS (median NR vs. 34.84 [26.68–47.60] mos, p  = 0.0316). Conclusions These real-world data confirm that FLOT treatment is effective in daily clinical practice for locally advanced GC/GEJC, also in the MSI-H/dMMR subgroup. It also showed a higher rate of nodal status downstaging and a better outcome of MSI-H/dMMR pts in comparison to MSS/pMMR.

• Publisher: Springer Berlin Heidelberg,Springer Nature B.V
• Subject: 5-Fluorouracil / Cancer Research / Cancer therapies / Chemotherapy / Clinical outcomes / drug therapy / elderly / females / Gastric cancer / Hematology / Internal Medicine / intestines / Lymph nodes / Lymphatic system / Medical prognosis / Medical research / Medicine / Medicine & Public Health / Microsatellite instability / microsatellite repeats / Mismatch repair / Mortality / neoplasms / Observational studies / Oncology / phenotype / Phenotypes / Population studies / Statistical analysis / Surgery / Tumors